Cecilia Brown
Articles by Cecilia Brown
The 60-day mortality rate was around twice as high in patients with KMT2A rearrangement.
While NPM1 mutations impacted CR rates, they had “no impact” on RFS and OS after each line of salvage therapy.
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in relapsed or refractory LBCL.
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Patients with clinical progression had a significantly shorter median OS from their first relapse.
Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A.
Hematopoietic stem/progenitor cells from patients with myelofibrosis are “enriched” for a CXCL8/CXCR2 gene signature.
A new study suggests CR with MRD negativity should be the “key objective" of high- and low-intensity therapy for AML.
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
A reduction in spleen volume reduction of ≥35% at 24 weeks occurred in 68% of patients.
Around two-thirds of second primary malignancies were solid malignancies and 20% were myeloid malignancies.
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
The “greatest benefit" was observed in those who had t(4;14) or amp1q21.
A phase I/II trial of LV20.19 showed a 100% ORR in patients with relapsed or refractory MCL.
Benefits of rituximab maintenance were observed despite the shift in first-line induction strategies over the years.
Frailty measures have been "increasingly incorporated" in multiple myeloma trials in recent years.
Brexucabtagene autoleucel in the standard-of-care setting for R/R MCL showed efficacy and toxicity “consistent” with ...
Treatment of LR-MDS remains an unmet need and goals of therapy should extend beyond transfusion independence.
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
The four-year OS rate from the first randomization was 94% in patients without high-risk cytogenetic abnormalites.
670 Madison Ave.
Manalapan, NJ 07726